EX-99.2
62
v208464_ex99-2.htm
NeoStem
Acquires Progenitor Cell Therapy
Becomes
single source for collection, storage, manufacturing, therapeutic development
and transportation of cells for cell
based
medicine and regenerative science globally
NEW YORK
and ALLENDALE, N.J., Jan. 20, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex:
NBS) and Progenitor Cell Therapy LLC announced today the closing of their
previously announced merger transaction. NeoStem is an international
biopharmaceutical company with a 51% ownership interest in a profitable Chinese
generic pharmaceutical manufacturing company and has stem cell operations in the
U.S. and China, while Progenitor Cell Therapy, LLC is a privately held cell
therapy company with operations on the east and west coast of the U.S. serving
the cell therapy community with cGMP state-of-the art cell therapy manufacturing
facilities, and processing and storage facilities for stem cells collected from
the umbilical cord at birth.
PCT's
revenue generating business will complement NeoStem's growing adult stem cell
operations and PCT's management adds to NeoStem the over 100 years' collective
experience of the PCT management team in the business and science of cell
therapy and its development. Since its inception in 1999, PCT has served over
100 clients from around the world and has experience with more than 20 different
cell based therapeutics. PCT has performed over 30,000 cell therapy procedures
in its cell therapy manufacturing facilities, and processed and stored over
18,000 cell therapy products (including approximately 7,000 umbilical cord blood
units, 10,000 blood and marrow derived stem cell units and 1,000 dendritic cell
units) and arranged the logistics and transportation for over 14,000 cell
therapy products for clinical use by over 5,000 patients.
Dr. Robin
Smith, MD, MBA, CEO of NeoStem said, "The merger with PCT is a significant step
toward NeoStem's goal of becoming a leader in the fast-growing Stem Cell
Industry, generating revenues, and developing and licensing therapies to be used
in the United States and abroad. We have purchased revenues and expertise, and
reduced NeoStem's prior expense line as PCT was a vendor to NeoStem. We are
developing a "one-stop-shop" global network of cell therapy core competencies by
adding cell therapy manufacturing and storage facilities as well as integrated
regulatory compliant distribution capacity for the evolving cell therapy
industry. The addition of PCT will allow NeoStem to focus on growing the cord
blood and adult stem cell banking, cellular manufacturing and therapeutic
business, as well as expanding our businesses in Asia and other countries, while
continuing to develop our intellectual property and acquire new
technology".
Dr.
Andrew Pecora, PCT's CEO, will continue his involvement with the combined
companies by shifting his role from PCT's Chief Executive Office to Chief
Medical Officer, and has been invited and has agreed to join the NeoStem Board
of Directors. Dr. Pecora said, "Our merger with NeoStem will provide the rapidly
developing cell therapy industry with a dynamic global development and
manufacturing platform that can accelerate the pace of commercialization of
future cell therapeutics".
LifeTech
Capital, an investment banking firm focused on the life science industry,
advised NeoStem by providing a valuation analysis of the transaction. LifeTech
Capital is a division of Aurora Capital LLC.
About
NeoStem, Inc.
NeoStem,
Inc. is an international biopharmaceutical company with adult stem cell
operations in the U.S., a network of adult stem cell therapeutic providers in
China as well as a 51% ownership interest in a profitable Chinese generic
pharmaceutical manufacturing company. NeoStem is focused on accelerating the
development of proprietary cellular therapies and becoming a single source for
collection, storage, manufacturing, therapeutic development and transportation
of cells for cell based medicine and regenerative science globally. The Company
also has licensed various cellular therapy technologies, including worldwide
exclusive licenses to a wound healing technology and to VSEL
™
Technology which uses very small embryonic-like stem cells, which are adult stem
cells that have been shown to have several physical characteristics that are
generally found in embryonic stem cells, and a T-cell regulatory technology
through the acquisition of Progenitor Cell Therapy, LLC.
For more
information, please visit:
http://www.neostem.com.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
reflect management's current expectations, as of the date of this press release,
and involve certain risks and uncertainties. Forward looking statements include
statements herein with respect to the ability of PCT's business to complement
NeoStem's adult stem cell operations and successful execution of the Company's
strategy, as well as other advances in the Company's business, about which no
assurances can be given. The Company's actual results could differ materially
from those anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to materially differ
from the recent results or those projected in forward-looking statements include
the "Risk Factors" described in the Company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission on March 31, 2010, its Form S-4/A
filed with the Securities and Exchange Commission on December 3, 2010 as well as
other periodic filings made with the Securities and Exchange Commission. The
Company's further development is highly dependent on future medical and research
developments and market acceptance, which is outside its control. NeoStem may
experience difficulties in integrating PCT's business and could fail to realize
potential benefits of the merger. Acquisitions may entail numerous risks for
NeoStem, including difficulties in assimilating acquired operations,
technologies or products, including the loss of key employees from acquired
businesses.
For more
information, please contact:
NeoStem,
Inc.
Robin
Smith, CEO
Phone:
+1-212-584-4174
Email:
rsmith@neostem.com
Web:
http://www.neostem.com
CONTACT:
NeoStem, Inc.: Robin Smith, CEO, +1-212-584-4174,
rsmith@neostem.com

EX - 99 . 2 62 v208464 _ ex99 - 2 . htm NeoStem Acquires Progenitor Cell Therapy Becomes single source for collection , storage , manufacturing , therapeutic development and transportation of cells for cell based medicine and regenerative science globally NEW YORK and ALLENDALE , N . J . , Jan. 20 , 2011 / PRNewswire / -- NeoStem , Inc . ( NYSE Amex : NBS ) and Progenitor Cell Therapy LLC announced today the closing of their previously announced merger transaction . NeoStem is an international biopharmaceutical company with a 51 % ownership interest in a profitable Chinese generic pharmaceutical manufacturing company and has stem cell operations in the U . S . and China , while Progenitor Cell Therapy , LLC is a privately held cell therapy company with operations on the east and west coast of the U . S . serving the cell therapy community with cGMP state - of - the art cell therapy manufacturing facilities , and processing and storage facilities for stem cells collected from the umbilical cord at birth . PCT 's revenue generating business will complement NeoStem 's growing adult stem cell operations and PCT 's management adds to NeoStem the over 100 years ' collective experience of the PCT management team in the business and science of cell therapy and its development . Since its inception in 1999 , PCT has served over 100 clients from around the world and has experience with more than 20 different cell based therapeutics . PCT has performed over 30,000 cell therapy procedures in its cell therapy manufacturing facilities , and processed and stored over 18,000 cell therapy products ( including approximately 7,000 umbilical cord blood units , 10,000 blood and marrow derived stem cell units and 1,000 dendritic cell units ) and arranged the logistics and transportation for over 14,000 cell therapy products for clinical use by over 5,000 patients . Dr . Robin Smith , MD , MBA , CEO of NeoStem said , " The merger with PCT is a significant step toward NeoStem 's goal of becoming a leader in the fast - growing Stem Cell Industry , generating revenues , and developing and licensing therapies to be used in the United States and abroad . We have purchased revenues and expertise , and reduced NeoStem 's prior expense line as PCT was a vendor to NeoStem . We are developing a " one - stop - shop " global network of cell therapy core competencies by adding cell therapy manufacturing and storage facilities as well as integrated regulatory compliant distribution capacity for the evolving cell therapy industry . The addition of PCT will allow NeoStem to focus on growing the cord blood and adult stem cell banking , cellular manufacturing and therapeutic business , as well as expanding our businesses in Asia and other countries , while continuing to develop our intellectual property and acquire new technology " . Dr . Andrew Pecora , PCT 's CEO , will continue his involvement with the combined companies by shifting his role from PCT 's Chief Executive Office to Chief Medical Officer , and has been invited and has agreed to join the NeoStem Board of Directors . Dr . Pecora said , " Our merger with NeoStem will provide the rapidly developing cell therapy industry with a dynamic global development and manufacturing platform that can accelerate the pace of commercialization of future cell therapeutics " . LifeTech Capital , an investment banking firm focused on the life science industry , advised NeoStem by providing a valuation analysis of the transaction . LifeTech Capital is a division of Aurora Capital LLC . About NeoStem , Inc . NeoStem , Inc . is an international biopharmaceutical company with adult stem cell operations in the U . S . , a network of adult stem cell therapeutic providers in China as well as a 51 % ownership interest in a profitable Chinese generic pharmaceutical manufacturing company . NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection , storage , manufacturing , therapeutic development and transportation of cells for cell based medicine and regenerative science globally . The Company also has licensed various cellular therapy technologies , including worldwide exclusive licenses to a wound healing technology and to VSEL ™ Technology which uses very small embryonic - like stem cells , which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells , and a T - cell regulatory technology through the acquisition of Progenitor Cell Therapy , LLC . For more information , please visit : http://www.neostem.com . Forward - Looking Statements This press release contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements reflect management 's current expectations , as of the date of this press release , and involve certain risks and uncertainties . Forward looking statements include statements herein with respect to the ability of PCT 's business to complement NeoStem 's adult stem cell operations and successful execution of the Company 's strategy , as well as other advances in the Company 's business , about which no assurances can be given . The Company 's actual results could differ materially from those anticipated in these forward - looking statements as a result of various factors . Factors that could cause future results to materially differ from the recent results or those projected in forward - looking statements include the " Risk Factors " described in the Company 's Annual Report on Form 10 - K filed with the Securities and Exchange Commission on March 31 , 2010 , its Form S - 4 / A filed with the Securities and Exchange Commission on December 3 , 2010 as well as other periodic filings made with the Securities and Exchange Commission . The Company 's further development is highly dependent on future medical and research developments and market acceptance , which is outside its control . NeoStem may experience difficulties in integrating PCT 's business and could fail to realize potential benefits of the merger . Acquisitions may entail numerous risks for NeoStem , including difficulties in assimilating acquired operations , technologies or products , including the loss of key employees from acquired businesses . For more information , please contact : NeoStem , Inc . Robin Smith , CEO Phone : + 1 - 212 - 584 - 4174 Email : rsmith@neostem.com Web : http://www.neostem.com CONTACT : NeoStem , Inc . : Robin Smith , CEO , + 1 - 212 - 584 - 4174 , rsmith@neostem.com
O O O O O O O O O O O O O B-Parties.BUYING_COMPANY O B-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY O O O O O O O B-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Advisors.GENERIC_CONSULTING_COMPANY I-Advisors.GENERIC_CONSULTING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Advisors.GENERIC_CONSULTING_COMPANY I-Advisors.GENERIC_CONSULTING_COMPANY I-Advisors.GENERIC_CONSULTING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O